ABSTRACT
The aim of this study was to assay of p53 antibodies in the serum of Syrian breast cancer patients, and to correlate these results with various clinical parameters. We also wanted to assess the prognostic significance of these antibodies in treatment monitoring and recurrence in patients. Serum of 60 patients of breast cancer, 35 patients of benign mass and 35 of control were analyzed using Enzyme linked immunoadsorbent assay ELISA. Eight of sixty breast cancer patients was positive for p53 antibodies [13.3%], one patient of benign mass patients were positive for p53 antibodies [2.9%] and p35 antibodies weren't detected in control group. The difference was statistically significant [p<0.05]. We observed an inverse relationship between the presence of p53 antibodies and the age of the patients. We found no significant association between the presence of p53 antibodies and tumor size. p53 antibodies were higher in patients with metastasis to axillary lymph nodes and advanced stages, but the difference was not statistically significant [p>0.05]. When we followed up patients of positive anti-p53 antibodies after surgery, chemotherapy or radiotherapy, there was a decrease in anti-p53 antibodies as a biomarker as well as a prognostic factor for patients with breast cancer